Evaxion A/S (EVAX)

Market Cap	34.36M
Revenue (ttm)	3.18M
Net Income (ttm)	-11.97M
Shares Out	6.32M
EPS (ttm)	-4.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	646,804
Open	6.09
Previous Close	6.53
Day's Range	5.29 - 6.31
52-Week Range	1.20 - 15.50
Beta	0.23
Analysts	Strong Buy
Price Target	13.50 (+148.16%)
Earnings Date	Nov 7, 2025

About EVAX

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vacci...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: EVAX
• Website: https://evaxion.ai

Financial Performance

In 2024, Evaxion's revenue was $3.34 million, an increase of 4480.82% compared to the previous year's $73,000. Losses were -$10.57 million, -52.24% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price target is $13.5, which is an increase of 148.16% from the latest price.

Price Target

$13.5

(148.16% upside)

Analyst Consensus: Strong Buy